An innovative research effort has revealed that administering stem cells to unborn babies suffering from spina bifida as part of a surgical repair can be a "important advancement" in treating birth defects.
Trial Details and Safety
The US-based trial involved six developing infants with the 'open' form of spina bifida. Medical teams placed placenta-derived mesenchymal stem cells directly onto the infant's spine as part of the surgical correction.
Importantly, the regenerative treatment proved to be secure. Researchers confirmed that the cells did not cause neoplasms, hinder surgical recovery, or impede the resolution of co-occurring hindbrain herniation.
Positive Developments
Imaging conducted after delivery showed a full resolution of brainstem displacement in all six infants. This favorable anatomical change is closely linked to better mobility and function.
"If it makes a greater number of infants capable of walking who wouldn't have, then it would become their standard of care," commented the principal investigator. "The outcomes appear profoundly encouraging and pave the way for numerous possible novel therapies."
Future Implications and Hope
Independent medical specialists have suggested that additional validation of these noted improvements could announce a "different age" in in-utero treatment. The prospect of enhancing neural deficits seen in utero is viewed as a paradigm-shifting aim.
Notably important would be improvements in continence and digestive health, which are common challenges for those diagnosed with this condition.
Future Directions
Although this preliminary study was small in scale, its safety demonstration and positive signals provide a strong foundation for larger, more comprehensive studies. The addition of cellular treatment with proven prenatal surgical methods presents significant potential for changing life trajectories for infants diagnosed prenatally with this neural tube defect.